Five-Year Cardiorenal Outcomes and Longitudinal Chronic Kidney Disease Screening in People with Type 2 Diabetes Managed by Endocrinologists: A Nationwide Retrospective Cohort Study.

Nearly one-third of people with type 2 diabetes experienced a kidney event over 5 years of follow-up.

• 31.1% of the 13,600 individuals experienced a kidney event over the 5-year study period (2018–2022).
• The cohort was drawn from the Telotron database comprising 2.2 million patients.
• Adults with T2D attended across both primary and endocrinology care settings were included.
• This finding applied across participants managed in routine real-world clinical practice.

Nearly one in five people with type 2 diabetes experienced a cardiovascular event over 5 years.

• 18.6% of participants experienced a cardiovascular event over the 5-year follow-up.
• The study population consisted of 13,600 individuals with T2D.
• Cardiovascular events were assessed as cumulative proportion over the study period.
• This occurred despite participants receiving care from endocrinology and primary care settings.

All-cause hospitalization and mortality were common in the study cohort over 5 years.

• 24.9% of participants experienced all-cause hospitalization over the 5-year period.
• 16.1% of the 13,600 participants died during the follow-up period.
• These outcomes were assessed from 1 January 2018 to 31 December 2022.
• These rates reflect outcomes in a real-world endocrinology and primary care managed population.

More than one-third of participants without baseline CKD developed a first abnormal eGFR or UACR measurement during follow-up.

• 37.0% of participants without baseline CKD had a first occurrence of an abnormal eGFR or UACR measurement during the 5-year follow-up.
• 45.4% of participants who had baseline CKD showed CKD progression over the study period.
• These findings highlight the substantial burden of incident and progressive kidney disease in this population.
• eGFR (estimated glomerular filtration rate) and UACR (urine albumin-to-creatinine ratio) were used as the screening measures.

Annual CKD monitoring was suboptimal, with low rates of both eGFR and UACR assessment in people with type 2 diabetes.

• Only 39.1% of participants underwent at least one yearly eGFR assessment.
• Only 16.6% of participants underwent at least one yearly UACR assessment.
• The mean number of eGFR measurements per patient over the study period was 2.9.
• The mean number of UACR measurements per patient over the study period was 1.5.
• UACR monitoring was notably less frequent than eGFR monitoring, indicating a particular gap in albuminuria screening.

The study used a nationwide retrospective cohort design drawing on anonymized data from the Telotron database.

• The Telotron database contains data from approximately 2.2 million patients.
• The study included 13,600 adults with T2D followed from 1 January 2018 to 31 December 2022.
• Participants were managed across both primary care and endocrinology settings.
• Outcomes assessed included kidney events, cardiovascular events, hospitalizations, mortality, and frequency of CKD screening measures.